CanaryIQ uses privacy-friendly, cookieless analytics (Fathom) to understand aggregate site usage. We don't use tracking cookies, we don't sell or share your data, and we honor Global Privacy Control. See our Privacy Policy.

Regulatory Policy

New regulations don’t just create constraints—they shape industries. CanaryIQ tracks global policy changes, identifying the emerging rules and decisions that will define the future of technology, investment, and competition.

Anticipate Regulatory Changes with Confidence

Get a Global View of Regulatory Change

Governments and regulators are shaping the future of technology. CanaryIQ tracks legislative developments and policy shifts worldwide—so you can see emerging regulations before they become law and understand their impact across industries.

The AI Act arrived in stages
  1. Entered into force
  2. Initial prohibitions and AI literacy rules
  3. Governance and GPAI obligations
  4. General application

    Exceptions and later high-risk deadlines remain.

Understand What the Rules Actually Cover

From AI governance to data privacy to emerging technology standards, new policies define how industries evolve. CanaryIQ breaks down the key regulations affecting your sector—helping you adapt, innovate, and stay ahead.

Who the AI Act affects
General-purpose AI

Model providers

Transparency and copyright obligations; additional duties for models with systemic risk.

Human interaction

Chatbots

People should know when they are interacting with AI.

Synthetic media

Generated content

Identification and disclosure requirements depend on the content and use.

Connect Regulatory Milestones to Technologies

Regulatory changes can create winners and losers. CanaryIQ connects policy decisions to industries, companies, and technologies—so you can anticipate market shifts before they happen.

CRISPR crosses a regulatory threshold
DEC082023

CASGEVY

FDA approval for sickle cell disease in patients aged 12 and older with recurrent vaso-occlusive crises.

CRISPR/Cas9 gene editing

A second FDA indication: transfusion-dependent β-thalassemia, ages 12 and older.

Turn Policy Changes Into Strategic Advantage